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Abstract
Background and Objectives: Lymphadenectomy during pulmonary metastasectomy
(PM) is widely carried out. We assessed the potential benefit on patient survival and
tumor recurrence of this practice.
Methods: One hundred eighty‐one patients undergoing a first PM were studied.
Eighty‐six patients (47.5%) underwent lymphadenectomy (L+ group) whereas 95
(52.5%) did not undergo nodal harvesting (L−group). Main outcomes were overall
survival (OS) and disease‐free survival (DFS). Median follow‐up was 25 months
(interquartile range [IQR], 13‐49).
Results: At follow‐up 84 patients (46.4%) died, whereas 97 (53.6%) were still alive
with recurrence in 78 patients (43%). There was no difference in 5‐year survival
(L+ 30.0% vs L− 43.2%; P = .87) or in the 5‐year cumulative incidence of recurrence
(L + 63.2% vs L−80%; P = .07) between the two groups. Multivariable analysis
indicated that disease‐free interval (DFI) less than 29 months (P < .001) and lung
comorbidities (P = .003) were significant predictors of death. Metastases from
non‐small–cell lung cancer increased the risk of lung comorbidities by a factor of
19.8, whereas the risk of DFI less than 29 months was increased nearly 11‐fold.
Competing risk regression identified multiple metastases (P = .004), head/neck
primary tumor (P = .009), and age less than 67 years (P = .024) as independent risk
factors for recurrence.
Conclusion: Associated lymphadenectomy showed not to give any additional
advantage in terms of survival and recurrence after PM.
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1 | INTRODUCTION
The oligometastatic disease was first defined by Hellman and
Weichselbaum in 19951 and indicates that patients are at an
intermediate state between a limited primary tumor and a
poly‐metastatic disease.2 Pulmonary metastasectomy (PM) has
become an acknowledged therapeutic option in the context of this
disease.3-5 The previous series have identified several factors
affecting survival3,6,7 but, in recent years, the attention has been
increasingly focused on the role of intrathoracic lymph nodes status
during PM.8-12 However, while it is widely accepted that systematic
nodal dissection during surgery aids in prognostic stratification and
identification of those patients with a higher risk of disease
progression9,11,12 little is still known as to whether performing
lymph nodes dissection during PM could influence patient survival as
well as tumor recurrence.12
Therefore, the aim of our study was to investigate whether
associated lymphadenectomy may affect mid‐term survival and
tumor recurrence in patients undergoing PM. Furthermore, we
aimed to identify predicting factor of these long‐term outcomes.
2 | MATERIALS AND METHODS
This paper was structured according to the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
statement.13
The approval was waived by Ethical Committee due to the
retrospective analysis of the study according to National Laws
regulating observational retrospective studies (Italian law no.11960,
released on 13 July 2004). However, written consent for the use of
clinical data for the scientific purpose was obtained from all patients.
2.1 | Patient population
Clinical records from patients undergoing lung metastasectomy with
curative intent between January 2005 and December 2017 in a
single institution (Santa Maria Della Misericordia University Hospital,
Udine, Italy) were reviewed. The population was divided into two
groups: (a) Subjects undergoing associated lymphadenectomy and
lymph node biopsy (L+) and (b) Patients who did not undergo
lymphadenectomy (L−). Patients characteristics are reported in
Table 1. One hundred eighty‐one patients underwent the first PM
with a total of 260 lung nodules excised, accounting for a median
number of metastases per patient of 1.43 (range, 1‐7). Eighty‐six
patients (47.5%) belonged to the L+ group, whereas 95 (52.5%) were
in the L− group. Lung comorbidities were mainly represented by
chronic obstructive pulmonary disease (COPD). Twenty‐four patients
were affected by (COPD) and one by interstitial lung disease.
A thoracic and abdominal computed tomography (CT) scan was
performed preoperatively to evaluate the operability of lung lesions
and to identify extra‐thoracic localizations of disease. When a CT
scan showed enlargement of intrathoracic lymph nodes, a positron
emission tomography (PET) scan was performed to assess metabolic
activity at this site.14 In case of suspicious nodal uptake, a
preoperative invasive mediastinal staging was carried out and
patients with histologically proven nodal involvement were excluded
from surgery. Fifty‐one patients had a PET scan done preoperatively
and three had evidence of positive mediastinal nodal uptake. Two
were investigated with cervical mediastinoscopy and one with
endobronchial ultrasound.
The follow‐up after the treatment of the primary tumor included
outpatient visit, thoracic and abdominal CT scan and blood test every
3 months for the first 2 year and every 6 months thereafter.
2.2 | Main outcomes and definitions
Main outcomes were survival and freedom from the first recurrence
of metastasis after surgery (disease‐free survival [DFS]).
Disease‐free interval (DFI) was defined as the time lapse between
resection of the primary tumor and first diagnosis of pulmonary
metastases whereas DFS was the period after PM without evidence
of tumor re‐recurrence.
Neoadjuvant treatment was defined as the administration of
chemotherapy or irradiation of a tumor before definitive surgical
treatment, in this case, referred to the primary neoplasm whereas an
adjuvant treatment was a systemic treatment administered after
surgical resection.
Tumorectomy was defined as the removal of a nodule along with
minimal surrounding normal pulmonary tissues. An “open approach”
was a surgical procedure through thoracotomy or sternotomy.
2.3 | Surgical indications
Indications for surgery were: (a) Controlled primary tumor; (b)
Absence of extra‐thoracic disease or extra‐thoracic localizations
judged amenable to local therapies. (c) Lung disease considered
suitable for complete resection. (d) Absent proven intrathoracic
lymph nodes involvement. (e) Predicted postoperative forced
expiratory volume in 1 second and diffusing capacity of the lung for
carbon monoxide more than 40%.15,16
Bilateral metastases or number of nodules were not considered as
exclusion criteria. Patients with evident macroscopic residual disease or
where resection had been performed only for the diagnostic purpose
were excluded from the analysis. Similarly, patients whose excised
nodules did not confirm their metastatic nature were excluded. Finally,
we included only patients who had not previously undergone previous
PM or other ablative treatment for the same disease.
2.4 | Surgery
Details on surgical procedures are reported in Table 2. Surgery was
performed both by video‐assisted thoracic surgery (VATS) or
standard thoracotomy based on anatomical considerations and
surgeon’s preferences. The extent of resection was minimal enough
to guarantee complete excision with negative margins, in view of a
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TABLE 1 Patients and tumor’s characteristics
All (n = 181) L− (n=95) L+ (n=86) P
Male sex 105 (58) 47 (49.5) 58 (67.4) .01
Age at surgery 66 (IQR 58‐70) 65 (IQR 55‐69) 67 (IQR 59‐73) .05
ASA
2 117 (64.7) 64 (67.4) 53 (61.6) .41
3 64 (35.3) 31 (32.6) 33 (38.4)
Comorbidities
Coronaropathy 14 (7.8) 5 (5.3) 9 (10.5) .19
Arrhythmia 13 (7.2) 7 (7.4) 6 (7) .91
Hypertension 70 (38.7) 32 (33.7) 38 (44.2) .14
Other cancers 39 (21.5) 16 (16.8) 23 (26.7) .10
Lung disease 25 (13.8) 16 (16.8) 23 (26.7) .21
Diabetes 17 (9.3) 9 (9.5) 8 (9.3) .96
Chronic renal failure 4 (2.2) 2 (2.2) 2 (2.3) .91
Liver disease 8 (4.4) 6 (6.3) 2 (2.3) .19
Other 40 (22.1) 18 (18.9) 22 (25.6) .28
Primary tumor
Colorectal 76 (42.0) 34 (35.8) 42 (48.8) .07
Gynecological 5 (2.8) 1 (1.0) 4 (4.7) .14
Melanoma 12 (6.6) 7 (7.4) 5 (5.8) .67
Breast 7 (3.9) 2 (2.2) 5 (5.8) .19
Head/neck 8 (4.4) 3 (3.2) 5 (5.8) .38
NSCLC 15 (8.3) 13 (13.6) 2 (2.3) .005
Kidney 25 (13.8) 12 (12.6) 13 (15.1) .62
Sarcoma 18 (10.0) 12 (12.6) 6 (7.0) .20
Other 15 (8.2) 11 (11.6) 4 (4.7) .09
Thyroid 3 (1.7) 3 (3.2) 0
Parathyroid 3 (1.7) 2 (2.2) 1 (1.2)
Cholangiocarcinoma 2 (1.1) 2 (2.2) 0
Pancreas 2 (1.1) 1 (1.0) 1 (1.2)
Liver 2 (1.1) 1 (1.0) 1 (1.2)
Bladder 1 (0.5) 1 (1.0) 0
Small bowel 1 (0.5) 0 1 (1.2)
Thoracic neurofibroma 1 (0.5) 1 (1.0) 0
RT/CHT
Neoadjuvant 25 (13.8) 13 (13.6) 12 (13.9) .95
Adjuvant 116 (64.1) 58 (61.1) 58 (67.4) .37
Number of lesions
1 136 (75.1) 70 (73.8) 66 (76.8) .40
2 30 (16.6) 15 (15.8) 15 (17.4)
3 6 (3.3) 4 (4.2) 2 (2.3)
4 2 (1.1) 0 2 (2.3)
5 5 (2.8) 4 (4.2) 1 (1.2)
6 1 (0.5) 1 (1.0) 0
7 1 (0.5) 1 (1.0) 0
DFI 29 (IQR 16‐54.5) 29 (IQR 14‐57) 29 (IQR 17‐40) .89
Note: Values are expressed as n (%) or median (interquartile range).
Abbreviations: ASA, American Society of Anesthesiologist score; CHT, chemotherapy; DFI, disease‐free interval; NSCLC, non‐small–cell lung cancer; RT,
radiotherapy.
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lung‐sparing surgery. Therefore, single peripheral lesions were
generally treated with wedge resections or segmentectomies,
whereas larger or central nodules or multiple lesions located to the
same lobe required major lung resections to be executed. Bilateral
metastases were approached with staged/synchronous bilateral
thoracotomy/VATS or median sternotomy.
Lymphadenectomy has been performed both as nodal sampling
and lobe‐specific lymph node dissection. In detail, 62.8% of patients
underwent both N1 and N2 nodal harvesting, 30.2% only N1 lymph
nodes biopsy and 7% only N2. 41.9% of patients were submitted to a
lobe‐specific nodal dissection (with excision of at least two N1 and
two N2 nodal stations), whereas 58.1% underwent a nodal sampling
with a median number of stations explored of 2 (IQR, 2‐3; range, 1‐5).
Nodal sampling was defined as picking of a limited number of lymph
nodes at specific N1‐N2 nodal stations, whereas a lobe‐specific node
dissection is defined as the complete removal of all visible lymph
nodes and surrounding fat tissue at level of the hylo‐mediastinal
stations specific for the lobe where the resection has been
performed, as defined by previous articles.17
In the L+ group, the lymph node specimens were histologically
analyzed and categorized according to the International System for
the staging of Lung Cancer.18
2.5 | Statistical analysis
The normality of distribution was assessed using the Kolmogorov‐
Smirnov test. Continuous data were summarized as mean and
standard deviation or median and 25th to 75th percentiles in case
of non‐normal distributions. Categorical variables were reported as
counts and percentages. Comparisons were carried out using Fisher’s
exact test and McNemar test where appropriate.
The Kaplan‐Meier method and log‐rank test were used for survival
analysis. A Cox regression model was used to estimate predictors of
death. The proportional hazard assumption was confirmed by use of
Schoenfeld residuals. Cumulative incidence curves were used to
graphically depict tumor recurrence and statistical significance was
tested with the Gray test. A competing risk analysis was used to avoid
overestimation of the incidence of recurrence.
TABLE 2 Operative approach and kind of resection
All (n = 181) L− (n = 95) L+ (n = 86) P
Resection
Tumorectomy 5 (2.8) 4 (4.2) 1 (1.2) 0.21
Wedge resection 105 (58.0) 82 (86.3) 23 (26.7) <.0001
Segmentectomy 12 (6.7) 6 (6.3) 6 (7.0) .85
Lobectomy 58 (32.0) 3 (3.2) 55 (64.0) <.0001
Bilobectomy 1 (0.5) 0 1 (1.1) .29
Pneumonectomy 0 0 0
Approach
VATS 85 (47) 55 (57.9) 30 (34.9) .002
Open 100 (55.2) 42 (44.2) 58 (67.4) .0017
Post‐resection status
R0 174 (96.1) 88 (92.6) 86 (100) .01
R+ 7 (3.9) 7 (7.4) 0
Note: Values are expressed as n (%).
Abbreviations: R0, no residual disease; R+, presence of residual disease; TH, thoracotomy; VATS, video‐assisted thoracic surgery.
TABLE 3 Complications
All (n = 181) L− (n = 95) L+ (n = 86) P
Complications
Total 27 (14.9) 10 (10.5) 17 (19.8) .08
Hemorrhage 4 (2.2) 2 (2.1) 2 (2.3) .92
Persistent air‐leak 8 (4.4) 2 (2.1) 7 (8.1) .02
AF 5 (2.8) 0 5 (5.81) .017
ARDS 2 (1.1) 0 2 (2.3) .13
Pneumonia 9 (5.0) 3 (3.2) 6 (7) .23
Other 12 (6.6) 4 (4.2) 8 (9.3) .17
Note: Values are expressed as n (%) or median (interquartile range).
Abbreviations: AF, atrial fibrillation; ARDS, acute respiratory distress syndrome.
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Cut‐offs were determined by receiver operating characteristic
(ROC) curves analysis as the optimal threshold for predicting death
and tumor recurrence. We validated the results using the bootstrap
method (1000 iterations). Subgroup analyses were performed testing
for interactions by entering interaction terms between each
subgroup and main predictors, with an interaction P < .10 considered
statistically significant. Furthermore, the effect of the main
predictors in each subgroup was tested at multivariable analysis.
R, release 3.2.3 (R Foundation for Statistical Computing, Wien,
Austria) software and “survival”, “cmprsk” and “forestplot” packages
were utilized. Significance for hypothesis testing was set at the .05
two‐tailed level.
3 | RESULTS
3.1 | Main outcomes
Overall, 20 patients had bilateral resections. Seventeen patients
(9.4%) were discovered with synchronous metastases at the time of
diagnosis of their primary tumor and underwent pre or postoperative
chemotherapy. Among the remainder 164 patients who developed
metachronous metastases, 83 (50.6%) received a systemic treatment
before or after PM. Administration of systemic treatment was
established by medical oncologists, based on patients’ and tumor
features.
Early results and postoperative complications are reported in
Table 3. At median follow‐up (100% complete) of 25 months (IQR 13‐
49 months, range 1‐155), 84 patients (46.4%) died, whereas 97
(53.6%) were still alive. Cancer progression was the cause of death in
67 patients (79.8%) whereas 17 (20.2%) died from other causes.
Median survival was 24.5 months (IQR, 13‐49) in the L+ group
and 25 months (IQR, 13‐48 months) in the L− group (P = .98). Median
DFS was 11 months (IQR, 5‐29 months) in both groups (P = .79).
Overall five‐year survival (Figure 1A) was 41.2% and there was no
difference in survival between the two groups (Figure 1B; P = .87).
Without considering patients with NSCLC, 5‐year survival was still
comparable (39.7% [28.2%‐54.8%] vs 43.8% [31.7%‐60.6%] in L+ and
L−, respectively, P > .9).
Recurrence of metastasis occurred in 78 (43%) patients (Table 4):
localized pulmonary recurrence was encountered in 34 (43.6%)
patients, whereas 44 (56.4%) patients developed lung and
F IGURE 1 A, Actuarial survival in the whole population. B,
Overall survival by groups (Lymphadenectomy, L+ and
no‐ lymphadenectomy, L−)
TABLE 4 Pattern of recurrence and treatment
All
(n = 78) Lung (n = 34, 43.6) Lung+extra pulmonary (n = 18, 23.1) Extra pulmonary only (n = 26, 33.3)
Surgery 34 (44.1) 22 (64.7) 3 (16.7) 9 (34.6)
Radiotherapy 7 (9.1) 1 (2.9) 1 (5.5) 5 (19.2)
Chemotherapy 29 (37.7) 10 (29.4) 11 (61.1) 8 (30.8)
No treatment 6 (7.8) 1 (2.9) 2 (11.1) 3 (11.5)
Other local treatmenta 1 (1.3) 0 0 1 (3.8)
Note: Values are expressed as n (%).
aTransarterial liver chemoembolization (TACE).
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extra‐pulmonary (n = 18) or isolated extra‐pulmonary (n = 26) metas-
tases. Treatment of recurrent metastases included further surgical
excision or radiotherapy (RT) for limited disease or systemic
therapies for widespread tumor diffusion or patients unfit or
unwilling to undergo surgical treatment. Of note, 64.7% of patients
who had limited lung recurrence were submitted for further surgical
resection, whereas systemic treatment has been proposed for 61.1%
of patients with the concomitant extra‐pulmonary disease.
Overall, 5‐year cumulative incidence of recurrence (Figure 2A)
was 72.5% (0.15% variance) and there was no statistically significant
difference between groups (Figure 2B; 80.0% [0.23% variance] vs
63.2% [0.37% variance], in L− and L+, respectively P = .073).
Corrected by NSCLC, these figures were 62.8% (0.38%) vs 80.8%
(0.29%) in L+ and L−, respectively, P = .06.
3.2 | Predictors of outcomes
Multivariable analysis indicated that DFI (P < .001) and lung
comorbidities (P = .003) were significant predictors of death
(Figure 3 A). Using a ROC curve the DFI cutoff was less than 29
months (AUC 0.71 [0.62‐0.79]). At competing risk regression
(Figure 3 B), multiple metastases (P = .004), head/neck primary tumor
(P = .009) and younger age (0.024) were identified as independent
risk factors for recurrence. At ROC curve the age cutoff was less than
67 years (AUC 0.73 [0.65‐0.82]). Pathological lymph node involve-
ment did not result in a significant predictor of recurrence (P = .21).
We found a significant interaction for death between lung
comorbidities and NSCLC (P = .025) and DFI less than 29 (P = .014).
At sub‐analysis, for death (Figure 4) NSCLC increased by 19.8 times
the risk of lung comorbidities and 10.7 times the risk of DFI less than
29 months.
Any significant interaction was also found for recurrence and sub‐
analysis. In addition, Figure 5 shows that the risk of recurrence was
lower when potential interacting variables were added.
Therefore, since adding the co‐factors hazard risk did not
increase, a number of metastases more than 2, head‐neck tumor
and age less than 67 were independent factors of recurrence.
4 | COMMENT
The present study was undertaken to investigate whether associated
lymphadenectomy could influence the midterm survival and tumor
recurrence in patients undergoing PM.
The main finding of our study is the absence of any significant
difference neither in midterm survival nor recurrence between
patients who underwent associated lymphadenectomy or not.
However, although not statistically significant, a trend towards a
lower re‐recurrence risk (80.0% vs 63.2%, P = .073) was observed in
the L+ group. The lack of benefits of lymphadenectomy has already
been reported by other groups.12 In addition, stereotactic body
radiotherapy (SBRT) is gaining increasing popularity and some trials
are ongoing comparing outcomes between surgery an SBRT.19 If the
results will confirm a non‐inferiority of SBRT over surgery, the
former might become an attractive option for this patients due to its
lower invasiveness and reduced overall risks.20 However, it must be
considered that, although the reported incidence of involved lymph
nodes is not high, the CT scan has a high incidence of false‐negative
and the positive predictive value of PET in detecting lymph node
involvement is low,21 thus rendering histological confirmation
necessary, even if the patient is offered a nonsurgical approach.
In our practice, we do not routinely use PET scan in the
preoperative workup of patients who are candidates to lung
metastasectomy, unless an intrathoracic nodal involvement is
F IGURE 2 A, Cumulative incidence of recurrence in the whole
population. B, Cumulative incidence of recurrence by groups
(lymphadenectomy, L+ and no‐ lymphadenectomy, L−)
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F IGURE 3 A, Predictors of death at
Cox Regression. B, Predictors of
recurrence at competing‐risk analysis. CI,
confidence interval; HR, hazard risk; SHR,
sub‐hazard risk. DFI, disease‐free interval
F IGURE 4 Sub‐analysis for death. A, Interaction between lung comorbidities and potential influencing factors. B, Interaction between
disease‐free survival (DFS) and potential influencing factors. CI, confidence interval; HR, hazard risk; NSCLC, non‐small–cell lung cancer
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suspected based on CT scan images. In accordance with our practice,
recent investigations showed how the number of metastases was
correctly identified both by CT and PET scan in only about 60% of
cases. Agreement between clinical and pathological nodal involve-
ment is quite low for both techniques, however with a little
advantage for PET scan.21 Therefore, given the impact of nodal
involvement on the prognosis of these patients we usually prefer to
reserve this investigation and delay surgical treatment only for
patients with high suspicion of more advanced disease.
Lymph node involvement is generally considered as the invasion
of tumor cells into local lymphatic vessels9 and a positive nodal status
indicates a marked aggressive behavior of some tumors with an
increased propensity to spread to lympho‐vascular structures9,12
resulting in a higher trend to further metastatic recurrence and
shorter overall survival. Lymphadenectomy has therefore been
advocated to allow a more accurate prognostic stratification as well
as a more accurate evaluation of the patients for potential adjuvant
treatments.11
F IGURE 5 Sub‐analysis for recurrence. A, Interaction between multiple metastases and potential influencing factors. B, Interaction between
head/neck tumor and potential influencing factors. C, Interaction between age and potential influencing factors. CI, confidence interval; SHR,
sub‐hazard risk
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Promoters of lymphadenectomy base their conviction on the
following postulates: (a) The identification of metastatically involved
lymph nodes undoubtedly carries a worse prognosis.22 (b) Mediast-
inal lymphadenectomy has a recognized low mortality and morbid-
ity.23 (c) In case of metastatic lymph nodes, lymphadenectomy might
increase the chance of removing all tumor deposits and a potential
source of further spreading.9
In our series and in accordance with what has been reported by
the International Registry,3 only 6.9% of patients who underwent
lymphadenectomy had histologically proven lymph nodal involve-
ment although other authors have described this figure to range
between 5% and 32%.3,8,12,21,24,25 We might hypothesize that the low
prevalence of nodal metastases might be due to our close follow‐up
protocol and the consequent early referral of patients and to the
strict preoperative work‐up to select candidates for surgical
treatment.
Another finding of our analysis, in accordance with large
retrospective studies,7,26 is that a short interval between primary
tumor resection and development of metastases (DFI < 29 months)
had a significant impact on survival with a 5% risk reduction per 1‐
month DFI increase. In addition, we found also that the presence of
lung comorbidities was associated with a 2.9‐fold rise of the risk of
death. In our series lung disease were mainly represented by
obstructive pulmonary disease (24 of 25, 96%). We might assume
that patients with lung comorbidities, and mainly those who already
underwent major lung resection for their primary tumor, may be
compromised from a functional point of view to safely undergo any
further surgical treatment, and therefore less effective systemic
treatments might have been undertaken under these circumstances.
This observation, from our point of view, confirms the current
indication for a lung‐sparing resection for pulmonary metastases,
resulting in adequate postoperative pulmonary function which
reflects in the good postoperative quality of life, both main pre‐
requisites when a surgical treatment option is offered to this subset
of patients.27,28 Therefore, wedge resection might be advisable when
both anatomical conditions and tumor extension allow a limited
pulmonary resection.28
Interestingly, whereas primary NSCLC alone was not an independent
risk factor of death and neither survival (P> .9) nor recurrence (P= .06)
was different between the two groups even corrected by this factor,
NSCLC increased the risk of death by about 20 times when associated
with lung disease and by more than 10 times if associated to DFI less
than 29 months. Whether this subset of patients is representative of a
particularly aggressive lung cancer histotype is unknown and, however,
beyond the scope of this investigation. However, in case of patients with
short DFI/or lung comorbidities, when concomitant signs of potential
NSCLC aggressiveness are present, such as the spreading of tumor cells
through the bronchial tree,29 both indication and surgical resection
extension might be questionable. Indeed, aerogenous tumor spread is an
acknowledged negative prognostic factor gaining increasing attention in
recent years.30 Under these circumstances, we believe that indication for
surgery should be carefully discussed by a multidisciplinary team and
tailored to the individual patient. Unfortunately, we currently have no
information to perform an analysis on this subset of patients, but this will
be the subject of further research.
Finally, multivariable analysis revealed three independent pre-
dictors of tumor recurrence:
(a) Multiple metastases increased the risk of developing a further
recurrence after surgery by more than 28% and this represented
something new since, whereas there was already evidence of its
influence on survival,3,25,31 its impact on recurrence had never
specifically investigated before. (b) Metastases arising from tumors of
the head and neck district were significantly associated with 3.3‐time
higher risk of recurrence. Also, this is a new finding since this factor
was explored only in small series with short follow and however only
in relation to survival.32,33 (c) Patients aged less than 67 years had a
significantly higher risk of tumor recurrence and this risk lowered by
2% per year increase. This is in contrast with the trend of results in
literature33,34 and it could be justified by the supposed tendency of
tumor cells to be more indolent in older hosts, although this has only
been demonstrated in murine experimental studies35 and still not
been confirmed in human clinical investigations.36
5 | LIMITATIONS
This study has some limitations: first, the retrospective design and
the relatively small number of patients impose some caution in
interpreting our results.
Furthermore, the study does not compare patients with
pathologic lymph node involvement in the setting of metastasectomy
and this might have introduced a bias to the study design.
Nonetheless, this was beyond the principal aim of the study mainly
focused on surgical lymphadenectomy that could help surgeons in
referring patients for potential adjuvant treatments.
Moreover, pathologists from our institution do not routinely
count the number of lymph nodes, therefore the median number of
lymph nodes excised cannot be defined.
Additionally, the small number within histotype‐subgroups did
not allow us to carry out an analysis by tumor type. We are collecting
data for ongoing research that will be focused on this subject.
However, many previous publications reported on pulmonary
metastases arising from different primitive tumors,3,37-40 and survival
estimates do not differ consistently between populations with single
or multiple histotypes of origin.41-45
6 | CONCLUSION
In our experience, associated lymphadenectomy did not give any
additional advantage in terms of survival and recurrence after
metastasectomy and it was not a predictive factor of these main
outcomes. Larger cohort prospective studies are necessary to
confirm our findings and to define the true prognostic impact of
lymphadenectomy during PM.
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